Metabolic complications and increased cardiovascular risks as a result of androgen deprivation therapy in men with prostate cancer - Abstract

Department of Medicine, Section of Endocrinology and Metabolism, Overton Brooks VA Medical Center, Shreveport, LA 71101, USA.

 

Prostate cancer is one of the most common malignancies in men. Charles Huggins and Clarence V. Hodges reported the androgen dependence of prostate cancer in 1941. That led to the utilization of androgen deprivation therapy as an important therapeutic modality to treat prostate cancer. Androgen deprivation therapy has additional systemic effects that include sexual dysfunction, psychological changes and more important are the metabolic changes. Metabolic changes in particular include insulin resistance, increase fat mass and low-density lipoprotein cholesterol, and induce type 2 diabetes. In this review we will focus on the cardiovascular risk associated with androgen deprivation therapy that includes the mechanisms involved.

Written by:
Shastri BR, Yaturu S.   Are you the author?

Reference: Prostate Cancer. 2011;2011:391576.
doi: 10.1155/2011/391576

PubMed Abstract
PMID: 22110984

UroToday.com Prostate Cancer Section

 

email news signup